

Chapter 128

Kaposi's Sarcoma and Angiosarcoma

Erwin Tschachler

REFERENCES

1. Kaposi M: Idiopathisches multiples Pigmentsarkom der Haut. *Arch Dermatol Syphil* 4:265, 1872
2. Giraldo G, Beth E, Haguenu F: Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions. *J Natl Cancer Inst* 49:1509, 1972
3. Beral V et al: Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? *Lancet* 335:123, 1990
4. Chang Y et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 266:1865, 1994
5. Dourmishev LA et al: Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. *Microbiol Mol Biol Rev* 67:175, 2003
6. Ganem D: KSHV and the pathogenesis of Kaposi sarcoma: Listening to human biology and medicine. *J Clin Invest* 120:939, 2010
7. Russo JJ et al: Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc Natl Acad Sci U S A* 93:14862, 1996
8. Neipel F, Albrecht JC, Fleckenstein B: Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: Determinants of its pathogenicity? *J Virol* 71:4187, 1997
9. Damania B: Oncogenic gamma-herpesviruses: Comparison of viral proteins involved in tumorigenesis. *Nat Rev Microbiol* 2:656, 2004
10. Cathomas G: Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) as a tumour virus. *Herpes* 10:72, 2003
11. Bais C et al: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. *Nature* 391:86, 1998
12. Guo HG et al: Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. *J Virol* 77:2631, 2003
13. Radkov SA, Kellam P, Boshoff C: The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. *Nat Med* 6:1121, 2000
14. Kaleeba JA, Berger EA: Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: Cystine transporter xCT. *Science* 311:1921, 2006
15. Rappocciolo G et al: Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. *J Virol* 82:4793, 2008
16. Dukers NH, Rezza G: Human herpesvirus 8 epidemiology: What we do and do not know. *AIDS* 17:1717, 2003
17. de Sanjose S et al: Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission. *J Infect Dis* 199:1449, 2009
18. Pauk J et al: Mucosal shedding of human herpesvirus 8 in men. *N Engl J Med* 343:1369, 2000
19. Cattani P et al: Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. *J Clin Microbiol* 37:1150, 1999
20. Engels EA et al: Risk of transfusion-associated transmission of human herpesvirus 8. *J Natl Cancer Inst* 91:1773, 1999
21. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. *N Engl J Med* 332:1181, 1995
22. Huang YQ et al: Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. *Lancet* 345:759, 1995
23. Sturzl M et al: Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. *J Natl Cancer Inst* 91:1725, 1999

24. Dupin N et al: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. *Proc Natl Acad Sci U S A* **96**:4546, 1999
25. Ablashi D et al: Seroprevalence of human herpesvirus-8 (HHV-8) in countries of southeast Asia compared to the USA, the Caribbean and Africa. *Br J Cancer* **81**:893, 1999
26. Whitby D et al: Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. *J Natl Cancer Inst* **90**:395, 1998
27. Veugelers PJ et al: Is the human immunodeficiency virus related Kaposi's sarcoma epidemic coming to an end? Insights from the tricontinental seroconverter study. *Epidemiology* **6**:382, 1995
28. Sullivan RJ et al: HIV/AIDS: Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. *Clin Infect Dis* **47**:1209, 2008.
29. Cronin DM, Warnke RA: Castleman disease: An update on classification and the spectrum of associated lesions. *Adv Anat Pathol* **16**:236, 2009
30. Chen KT: Multicentric Castleman's disease and Kaposi's sarcoma. *Am J Surg Pathol* **8**:287, 1984
31. Weninger W et al: Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. *Lab Invest* **79**:243, 1999
32. Gessain A, Duprez R: Spindle cells and their role in Kaposi's sarcoma. *Int J Biochem Cell Biol* **37**:2457, 2005
33. Wang HW et al: Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. *Nat Genet* **36**:687, 2004
34. Hong YK et al: Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. *Nat Genet* **36**:683, 2004
35. Henry M et al: Infection of circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma. *J Invest Dermatol* **113**:613, 1999
36. Rabkin CS et al: Monoclonal origin of multicentric Kaposi's sarcoma lesions. *N Engl J Med* **336**:988, 1997
37. Gil PS et al: Evidence for multiclonality in multicentric Kaposi's sarcoma. *Proc Natl Acad Sci U S A* **95**:8257, 1998
38. Judde JG et al: Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. *J Natl Cancer Inst* **92**:729, 2000
39. Duprez R et al: Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. *J Natl Cancer Inst* **99**:1086, 2007
40. Iscovich J et al: Classic Kaposi's sarcoma: Epidemiology and risk factors. *Cancer* **88**:500, 2000
41. Brenner B et al: Classical Kaposi sarcoma: Prognostic factor analysis of 248 patients. *Cancer* **95**:1982, 2002
42. Brambilla L et al: Mediterranean Kaposi's sarcoma. Associated pathology in a case study of 100 patients. *G Ital Dermatol Venereol* **123**:477, 1988
43. Thijs A: L'angiosarcomatose de Kaposi au Congo belge et au Ruanda-Urundi. *Ann Soc Belge Med Trop* **37**:295, 1957
44. Cook-Mozaffari P et al: The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. *Br J Cancer* **78**:1521, 1998
45. Taylor JF et al: Kaposi's sarcoma in Uganda: A clinico-pathological study. *Int J Cancer* **8**:122, 1971
46. Templeton AC, Bhana D: Prognosis in Kaposi's sarcoma. *J Natl Cancer Inst* **55**:1301, 1975
47. Dutz W, Stout AP: Kaposi's sarcoma in infants and children. *Cancer* **13**:684, 1960
48. Harwood AR et al: Kaposi's sarcoma in recipients of renal transplants. *Am J Med* **67**:759, 1979
49. Penn I: Kaposi's sarcoma in organ transplant recipients: Report of 20 cases. *Transplantation* **27**:8, 1979
50. Penn I: Kaposi's sarcoma in organ transplant recipients. *Transplantation* **64**:669, 1997
51. Greenfield DI et al: Kaposi's sarcoma in a patient with SLE. *J Rheumatol* **13**:637, 1986
52. Halpern SM et al: Kaposi's sarcoma associated with immunosuppression for bullous pemphigoid. *Br J Dermatol* **37**:140, 1997
53. Deschenes I et al: Kaposi's sarcoma following immune suppressive therapy for Wegener's granulomatosis. *J Rheumatol* **30**:622, 2003
54. Barette S et al: Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipients. *Arch Dermatol* **136**:1452, 2000

55. Centers for Disease Control: Kaposi's sarcoma and *Pneumocystis carinii* pneumonia among homosexual men—New York City and California. *MMWR Morb Mortal Wkly Rep* 25:305, 1981
56. Hermans P et al: Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. *AIDS* 10:911, 1996
57. Renwick, N et al: Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. *AIDS* 12:2481, 1998.
58. Ziegler JL, Katongole-Mbidde E: Kaposi's sarcoma in childhood: An analysis of 100 cases from Uganda and relationship to HIV infection. *Int J Cancer* 65:200, 1996
59. Sasco AJ et al: The challenge of AIDS-related malignancies in sub-Saharan Africa. *PLoS One* 5:e8621, 2010
60. Ficarra G et al: Kaposi's sarcoma of the oral cavity: A study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects, and treatment. *Oral Surg Oral Med Oral Pathol* 66:543, 1998
61. Tappero JW et al: Kaposi's sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. *J Am Acad Dermatol* 28:371, 1993
62. Gill PS et al: Pulmonary Kaposi's sarcoma: Clinical findings and results of therapy. *Am J Med* 87:57, 1989
63. Ioachim HL et al: Kaposi's sarcoma of internal organs: A multiparameter study of 86 cases. *Cancer* 75:1376, 1995
64. Ackerman AB: Subtle clues to diagnosis by conventional microscopy: The patch stage of Kaposi's sarcoma. *Am J Dermatopathol* 1:165, 1979
65. Cockerell CJ: Histopathological features of Kaposi's sarcoma in HIV infected individuals. *Cancer Surv* 10:73, 1991
66. Chor PJ, Santa Cruz DJ: Kaposi's sarcoma. A clinicopathologic review and differential diagnosis. *J Cutan Pathol* 19:6, 1992
67. Arav-Boger R: Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments. *Virus Genes* 38:195, 2009
68. Aoki Y, Tosato G: Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders. *Expert Rev Anti Infect Ther* 2:213, 2004
69. Hengge UR et al: Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. *Lancet Infect Dis* 2:281, 2002
70. Levine AM, Tulpule A: Clinical aspects and management of AIDS-related Kaposi's sarcoma. *Eur J Cancer* 37:1288, 2001
71. Karrer S et al: Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. *Am J Clin Dermatol* 2:229, 2001
72. Walmsley S et al: Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. *J Acquir Immune Defic Syndr* 22:235, 1999
73. Housri N, Yarchoan R, Kaushal A: Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary? *Cancer* 116:273, 2010
74. Northfelt DW: Treatment of Kaposi's sarcoma. Current guidelines and future perspectives. *Drugs* 48:569, 1994
75. Mocroft A et al: The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: The EuroSIDA Study. *Cancer* 100:2644, 2004
76. Martin-Carbonero L et al: Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. *AIDS* 18:1737, 2004.
77. Gill PS et al: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 14:2353, 1996
78. Stewart S et al: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. *J Clin Oncol* 16:683, 1998.
79. Northfelt DW et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. *J Clin Oncol* 16:2445, 1998
80. Hengge UR et al: Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. *Eur J Cancer* 37:878, 2001
81. Cooley T et al: A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. *Oncologist* 12:114, 2007

82. Cianfrocca M et al: Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy. *Cancer* **116**(16):3969-3977, 2010
83. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV: Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. *Transplantation* **77**:760, 2004
84. Stallone G et al: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. *N Engl J Med* **352**:1317, 2005
85. Safai B: Kaposi's sarcoma: An overview of classical and epidemic forms. In: *AIDS, Modern Concepts and Therapeutic Challenges*, edited by S Broder. New York, Marcel Dekker, 1987, p. 205
86. Di Lorenzo G: Update on classic Kaposi sarcoma therapy: New look at an old disease. *Crit Rev Oncol Hematol* **68**:242, 2008
87. Kreuter A et al: Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. *Cancer Invest* **23**:653, 2005
88. Beyeler M et al: The spectrum of mesenchymal skin neoplasms reflected by the new WHO classification. *Onkologie* **27**:401, 2004
89. Jones EW: Malignant angioendothelioma of the skin. *Br J Dermatol* **76**:2, 1964
90. Holden CA, Spittle MF, Jones EW: Angiosarcoma of the face and scalp, prognosis and treatment. *Cancer* **59**:1046, 1987
91. Stewart FW, Treves N: Lymphangiosarcoma in postmastectomy lymphedema, *Cancer* **1**:64, 1948
92. Goette DK, Detlefs RL: Postirradiation angiosarcoma. *J Am Acad Dermatol* **12**:922, 1985
93. Breiteneder-Geleff S et al: Angiosarcoma express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. *Am J Pathol* **154**:385, 1999
94. Budd GT: Management of angiosarcoma. *Curr Oncol Rep* **4**:515, 2002
95. Sasaki R et al: Angiosarcoma treated with radiotherapy: Impact of tumor type and size on outcome. *Int J Radiat Oncol Biol Phys* **52**:1032, 2002
96. Wollina U et al: Angiosarcoma of the scalp: Treatment with liposomal doxorubicin and radiotherapy. *J Cancer Res Clin Oncol* **127**:396, 2001
97. Abraham JA et al: Treatment and outcome of 82 patients with angiosarcoma. *Ann Surg Oncol* **14**:1953, 2007
98. Skubitz KM, Haddad PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. *Cancer* **104**:361, 2005
99. Maki RG et al: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol* **27**:3133, 2009
100. Donghi D, Dummer R, Cozzio A: Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. *Br J Dermatol* **162**:697, 2010